Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5 and 12 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Gastric Cancer, Metastatic Renal Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Hematological Tumor, Melanoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified Neurologic Disorders, Ureter Cancer and Urethral Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
• The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope